[Functional activity of placental, splenic and hepatic tissues in pyo-septic diseases under conditions of extracorporeal detoxication].
Immunocorrective and detoxication treatment by plasma perfusion through fragments of alloplacental tissue (group 1), fragments of xenosplenic tissue (group 2) and isolated xenohepatocytes (group 3) was carried out as an adjuvant therapy in 61 patients with pyoseptic diseases. Control group consisted of 21 patients. Comparative analysis of effectiveness of the treatment showed, that in patients of group 2 after 5 days substantial increase of lymphocytes count was detected due to increased pool of T- and B-lymphocytes. In patients of group 1 increase in lymphocytes content occurred even in greater degree, but it occurred mainly owing to the augmentation of B-lymphocytes pool. In patients of groups 1 and 2 already to the 3rd day an increase of FAL as well IgA and IgM occurred. There was no immunocorrective effect in patients of group 3, as well as control group. However, detoxication activity, having been evaluated by bilirubin and cytolytic enzymes dynamics, by urea and kreatinine level increased in all patients of groups 1, 2, 3 in comparison with the control. It is suggested, that allogenic placental tissue could be recommended for the treatment of pyoseptic conditions, especially in patients with transplanted organs, because this tissue electively activates only humoral immunity.
Pisarevskiĭ
A A
AA
Onishchenko
N A
NA
Zhuravlev
I V
IV
Orzhekhovskaia
I G
IG
Polosina
O V
OV
D000293:Adolescent; D000328:Adult; D000368:Aged; D001402:B-Lymphocytes / Q000276:immunology; D005260:Female; D006801:Humans; D008099:Liver / Q000502:physiology*; D016031:Liver Transplantation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010920:Placenta / Q000502:physiology*; D011247:Pregnancy; D018805:Sepsis / Q000276:immunology / Q000628:therapy*; D016060:Sorption Detoxification / Q000379:methods*; D013154:Spleen / Q000502:physiology* / Q000637:transplantation; D013492:Suppuration / Q000276:immunology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome